MA34642B1 - Anticorps dirigé contre le tweak humain et leurs utilisations - Google Patents

Anticorps dirigé contre le tweak humain et leurs utilisations

Info

Publication number
MA34642B1
MA34642B1 MA35867A MA35867A MA34642B1 MA 34642 B1 MA34642 B1 MA 34642B1 MA 35867 A MA35867 A MA 35867A MA 35867 A MA35867 A MA 35867A MA 34642 B1 MA34642 B1 MA 34642B1
Authority
MA
Morocco
Prior art keywords
tweak
diseases
directed against
antibodies directed
against human
Prior art date
Application number
MA35867A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34642B1 publication Critical patent/MA34642B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)

Abstract

L'invention concerne un anticorps se liant à TWEAK, caractérisé par la liaison à TWEAK, caractérisé en ce qu'il comprend en tant que domaine variable de la chaîne lourde un CDR3H choisi dans le groupe consistant en SEQ ID NO: 8, 16 ou 24, qui est utile pour le traitement du cancer ou de maladies auto-immunes, de la polyarthrite rhumatoïde, de la polyarthrite psoriasique, de maladies musculaires, par exemple la dystrophie musculaire, de la sclérose en plaque, de maladies rénales chroniques, de maladies osseuses, par exemple la dégénérescence osseuse dans des myélomes multiples, du lupus érythémateux disséminé, de la néphropathie lupique et de lésions vasculaires.
MA35867A 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations MA34642B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05
PCT/EP2011/067070 WO2012045671A1 (fr) 2010-10-05 2011-09-30 Anticorps dirigé contre le tweak humain et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34642B1 true MA34642B1 (fr) 2013-11-02

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35867A MA34642B1 (fr) 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations

Country Status (21)

Country Link
US (1) US9187564B2 (fr)
EP (1) EP2625200A1 (fr)
JP (1) JP5941049B2 (fr)
KR (1) KR101584416B1 (fr)
CN (1) CN103154029B (fr)
AR (1) AR083336A1 (fr)
AU (1) AU2011311673B2 (fr)
BR (1) BR112013007293A2 (fr)
CA (1) CA2809632A1 (fr)
CL (1) CL2013000901A1 (fr)
CR (1) CR20130108A (fr)
EA (1) EA201300418A1 (fr)
EC (1) ECSP13012542A (fr)
HK (1) HK1186195A1 (fr)
MA (1) MA34642B1 (fr)
MX (1) MX343114B (fr)
NZ (1) NZ607588A (fr)
PE (1) PE20131411A1 (fr)
SG (1) SG188605A1 (fr)
TW (1) TWI482630B (fr)
WO (1) WO2012045671A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387538A (zh) * 1999-01-15 2002-12-25 比奥根公司 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
WO2003086311A2 (fr) 2002-04-09 2003-10-23 Biogen, Inc. Procede pour traiter les etats lies a tweak
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
WO2012116926A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Protéines de liaison à un antigène
KR101674784B1 (ko) * 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
US20160243224A1 (en) * 2013-10-04 2016-08-25 Biogen Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
EP3174897B1 (fr) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
AU7668696A (en) 1995-11-03 1997-05-22 Austin Research Institute, The Methods and compositions for the reduction of xenotransplantation rejection
SK288012B6 (sk) 1996-08-07 2012-10-02 Biogen Idec Ma Inc. DNA coding ligand related to TNF, process for its preparation and method for inhibiting immune response
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
CN1387538A (zh) * 1999-01-15 2002-12-25 比奥根公司 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
WO2003086311A2 (fr) 2002-04-09 2003-10-23 Biogen, Inc. Procede pour traiter les etats lies a tweak
WO2004106381A1 (fr) 2003-05-31 2004-12-09 Micromet Ag Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b
CA2534639C (fr) 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
WO2006052926A2 (fr) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006088890A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de l'accident vasculaire cerebral
CA2597485A1 (fr) * 2005-03-07 2006-09-14 Genentech, Inc. Methodes et compositions de modulation de l'activite de tweak et de fn14
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
LT2460831T (lt) 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
WO2006133450A2 (fr) 2005-06-08 2006-12-14 Duke University Therapie a anticorps diriges contre cd19 a des fins de transplantation
WO2007002223A2 (fr) 2005-06-20 2007-01-04 Medarex, Inc. Anticorps cd19 et utilisations
US20070041979A1 (en) 2005-08-19 2007-02-22 Raju T S Proteolysis resistant antibody preparations
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008057634A2 (fr) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
SG188605A1 (en) 2013-04-30
MX343114B (es) 2016-10-25
EP2625200A1 (fr) 2013-08-14
US9187564B2 (en) 2015-11-17
NZ607588A (en) 2014-02-28
BR112013007293A2 (pt) 2016-06-14
JP2013543383A (ja) 2013-12-05
HK1186195A1 (zh) 2014-03-07
ECSP13012542A (es) 2013-06-28
AU2011311673A1 (en) 2013-03-14
CN103154029B (zh) 2015-11-25
EA201300418A1 (ru) 2013-09-30
JP5941049B2 (ja) 2016-06-29
CA2809632A1 (fr) 2012-04-12
AU2011311673B2 (en) 2015-09-17
TW201219054A (en) 2012-05-16
MX2013003592A (es) 2013-05-31
PE20131411A1 (es) 2013-12-16
US20120121583A1 (en) 2012-05-17
CR20130108A (es) 2013-04-29
CL2013000901A1 (es) 2013-11-29
AR083336A1 (es) 2013-02-21
KR20130062369A (ko) 2013-06-12
KR101584416B1 (ko) 2016-01-13
CN103154029A (zh) 2013-06-12
WO2012045671A1 (fr) 2012-04-12
TWI482630B (zh) 2015-05-01

Similar Documents

Publication Publication Date Title
MA34642B1 (fr) Anticorps dirigé contre le tweak humain et leurs utilisations
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MX2009006891A (es) Anticuerpos cd44.
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2009048537A3 (fr) Anticorps humanisé
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA31308B1 (fr) Anticorps antisclerostine.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
TW200740844A (en) Novel MAdCAM antibodies
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
EA201000424A1 (ru) Антитела к il-23
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA33387B1 (fr) Polypeptides et procede de traitement
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора